Endothelial Glycocalyx Shedding Emerges as a Dual Marker for Treatment and Diagnosis in Anaphylaxis
Journal of Investigational Allergology and Clinical Immunology · 21.07.2026 · 37 (5)
DOI: 10.18176/jiaci.1190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigational Allergology and Clinical Immunology, online erschienen am 21.07.2026. Verfasst von Lucía Palacio-García und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain.
Abstract (Originalsprache)
Background
Anaphylaxis is an acute life-threatening reaction. Research into the vascular endothelium and its components may improve disease management and patient outcomes.
Objective
We investigated the endothelial glycocalyx (eGCX) and its role in the pathophysiology of murine anaphylaxis, aiming to identify novel diagnostic and therapeutic targets.
Methods
Active systemic anaphylaxis (ASA) was evaluated in mice. eGCX structure and N-acetylglucosamine residues in mouse aortic tissue were analyzed using transmission electron microscopy and wheat germ agglutinin staining. Endocan (ESM-1) levels in mouse aorta and plasma were determined using immunofluorescence and ELISA. Sulodexide was administered as a prophylactic treatment. Human sera from ß-lactam–induced anaphylaxis and endothelial cell (EC) secretome samples were also analyzed. Results: eGCX surface area and thickness were reduced in ASA mice. N-acetylglucosamine and ESM-1 levels decreased in aortic tissue but increased in plasma, indicating eGCX shedding. Consistently, ESM-1 secretion was enhanced in ECs exposed to acute anaphylactic sera. ESM-1 and hyaluronic acid levels differed significantly between patients with anaphylaxis and nonallergic controls. Sulodexide reduced reaction severity, increased survival, and prevented disruption of eGCX and release of ESM-1. Conclusions: eGCX shedding, particularly of ESM-1, acts as a key mediator in murine anaphylaxis. Prophylaxis with sulodexide protects against severe reactions and improves survival. Therapies based on glycosaminoglycans and proteoglycans may mitigate the severity of anaphylaxis, and monitoring of eGCX dynamics could aid diagnosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain.
- Department of Vascular Pathology, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain.
- Department of Biochemistry and Molecular Biology, Faculty of Chemistry, Complutense University of Madrid, Madrid, Spain.
- Facultad de Ciencias Biomédicas y de la Salud, Universidad Alfonso X El Sabio, Madrid, Spain.
- RICORS-REI.
- Allergy Unit, Allergo-Anaesthesia, Unit, Hospital Central de la Cruz Roja, Madrid, Spain.
Zitieren
APA
Palacio-García, L., Fernández-Bravo, S., de María-Camacho, I., San Sebastián-Jaraba, I., Fernández-Gómez, M. J., López-Pérez, Ó., Sanz-Andrea, S., Pastor-Vargas, C., Nuñez-Borque, E., Laguna, J. J., Valverde, M., Blanco-Colio, L. M., Esteban, V., & Méndez-Barbero, N. (2026). Endothelial Glycocalyx Shedding Emerges as a Dual Marker for Treatment and Diagnosis in Anaphylaxis. Journal of Investigational Allergology and Clinical Immunology, 37(5). https://doi.org/10.18176/jiaci.1190
Vancouver
Palacio-García L, Fernández-Bravo S, de María-Camacho I, San Sebastián-Jaraba I, Fernández-Gómez MJ, López-Pérez Ó, et al. Endothelial Glycocalyx Shedding Emerges as a Dual Marker for Treatment and Diagnosis in Anaphylaxis. Journal of Investigational Allergology and Clinical Immunology. 2026;37(5). doi:10.18176/jiaci.1190
BibTeX
@article{PalacioGarca2026,
author = {Palacio-García, Lucía and Fernández-Bravo, Sergio and de María-Camacho, Irene and San Sebastián-Jaraba, Irene and Fernández-Gómez, María José and López-Pérez, Óscar and Sanz-Andrea, Sandra and Pastor-Vargas, Carlos and Nuñez-Borque, Emilio and Laguna, José Julio and Valverde, Marcela and Blanco-Colio, Luis Miguel and Esteban, Vanesa and Méndez-Barbero, Nerea},
title = {Endothelial Glycocalyx Shedding Emerges as a Dual Marker for Treatment and Diagnosis in Anaphylaxis},
journal = {Journal of Investigational Allergology and Clinical Immunology},
year = {2026},
volume = {37},
number = {5},
doi = {10.18176/jiaci.1190}
}
EUVIMED